Breast Cancer Quiz

Quiz

Quiz: Cost-Effectiveness of Margetuximab vs Trastuzumab for Breast Cancer

06/30/2022

True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...

True or False: Under a...

06/30/2022

Journal of Clinical Pathways

Quiz

Quiz: Trastuzumab Biosimilar for HER2-Positive Breast Cancer

03/17/2022

True or False: Trastuzumab biosimilars are safe and effective compared to the reference drug and improve patients' accessibility to breast cancer treatment.

True or False: Trastuzumab...

03/17/2022

Journal of Clinical Pathways

Quiz

Quiz: Cost-Effectiveness of Treatments for Low-Risk Ductal Carcinoma in Situ

09/17/2021

True or False: No adjuvant therapy is the most cost-effective approach for postmenopausal women who receive partial mastectomy for low-risk ductal carcinoma in situ.

True or False: No adjuvant...

09/17/2021

Journal of Clinical Pathways

Quiz

Quiz: Impact of Risk Factors on Incidence of Febrile Neutropenia in Patients With Breast Cancer

08/16/2021

True or False: The choice of febrile neutropenia (FN) definition significantly changes the impact of risk factors on FN outcomes among patients with breast cancer receiving chemotherapy with pegfilgrastim prophylaxis.

True or False: The choice of...

08/16/2021

Journal of Clinical Pathways

Quiz

Quiz: Progression-Free Survival Among Patients With Breast Cancer and PIK3CA Mutations

07/12/2021

True or False: Patients with breast cancer and PIK3CA mutations who receive alpelisib plus fulvestrant have longer real-world progression-free survival compared with those who receive fulvestrant alone.

True or False: Patients with...

07/12/2021

Journal of Clinical Pathways

Quiz

Quiz: Adjuvant Hormonal Therapy Adherence Rates Among Patients With Breast Cancer

05/03/2021

Journal of Clinical Pathways

Quiz

Quiz: How Can We Optimize Genetic Testing for Breast and Ovarian Cancer?

03/17/2021

Journal of Clinical Pathways

Quiz

Quiz: Cost-Effectiveness of Targeted Genetic Testing for Breast and Ovarian Cancer

03/05/2021

Journal of Clinical Pathways

Quiz

Quiz: Does Circulating Tumor Cell Count Help Determine Best Therapy Approach for Metastatic Breast Cancer?

01/28/2021

Journal of Clinical Pathways

Quiz

Quiz: Cost-Effectiveness of Genomic Screening for Breast and Ovarian Cancer

12/30/2020

Journal of Clinical Pathways

Current Issue

October 2024

Volume 10

Issue 5

Current Issue

Issue Archive

Special Reports

Sponsored

JCP Special Report

The Value of Tissue-Based Genomic Profiling in Oncology

09/17/2024

Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.

Innovations in precision...

09/17/2024

Journal of Clinical Pathways

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee ;

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Robin T. Zon , MD, FACP, FASCO;

Gordon Kuntz ;

Winston Wong , PharmD;

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan ;

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Breast Cancer Quiz

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products